

**Amendments to the Specification**

In the specification, please amend the summary of the invention on page 20 at line 2, to include the following:

-- This invention also relates to a method of predicting the receptor-modulating activity of a test compound when bound to a receptor, comprising the steps of:

(1) (a) providing a receptor;

(b) contacting the receptor with a plurality of reference compounds, the reference compounds known to modulate the biological activity of the receptor, and wherein the binding of each reference compound to the receptor forms a reference conformation;

(c) providing a panel comprising a plurality of members, wherein each member of the panel possesses differential ability to bind to the reference conformation;

(d) contacting the reference conformation with the panel;

(e) measuring the effect of the reference compound on the binding of the panel members to the receptor, the measuring step forming a fingerprint for each member of the plurality of reference compounds;

(2) (a) providing a test compound;

(b) contacting the receptor with the test compound, wherein the binding of the test compound to the receptor forms a test conformation;

(c) contacting the test conformation with the panel;

(d) measuring the effect of the test compound on the binding of the panel member; and

(3) comparing the effect of the test compound on the binding of the panel member to the fingerprints to predict the receptor-modulating activity of the test substance when bound to the receptor.

Additionally, the invention relates to the method as outlined above, where the fingerprint for each member of the plurality of reference compounds comprises a plurality of panel-based descriptors, each panel-based descriptor characterizing the effect of the reference compound on the binding of a particular panel member to the receptor, the panel-based descriptors collectively characterizing the effect of the reference compound on the binding of all of the panel members, individually, to the receptor.--

In the Specification, at page 238, please replace the paragraph with the following:

Other ER binding peptides include

SSKYSYSRSSEGHSR (SEQ ID NO: 59)

SSYQWETHSDKWRSR (SEQ ID NO: 60)

SSVTKKALTIKDSR (SEQ ID NO: 61)

The latter two are weak binders of ER in presence of estradiol.

In the Specification, at page 239, please replace Table 3 with the following:

Table 3: Phage/Peptide Classification

<u>Class 1</u>	<u># and isolation method</u>	
S S N H Q S S R L I E L L S R (SEQ ID NO: 62)	#4	ER + estradiol
S R L K E L L L L P T D L S R (SEQ ID NO: 63)	#15	ER + estradiol
S S K L Y C L L D E S Y C S R (SEQ ID NO: 64)	#35	ER + estradiol
H G P L T L N L L R S S G G (SEQ ID NO: 65)	#41	ER + estradiol
S R L E Y W L K W E P G P S R (SEQ ID NO: 66)	#12	ER + estradiol
<u>Class 2</u>		
S S C K W Y E K C S G L W S R (SEQ ID NO: 67)	#7	ER
S S E Y C F Y W D S A H C S R (SEQ ID NO: 68)	#33	ER + estradiol
S S W V L L R D L P W G S R (SEQ ID NO: 69)	#31	ER
S S W V R L S D F P W G V S R (SEQ ID NO: 70)	#24	ER + estradiol
<u>Class 3</u>		
S S L T S R D F G S W Y A S R (SEQ ID NO: 71)	#5	ER + estradiol
<u>Class 4</u>		
S R T W E S P L G T W E W S R (SEQ ID NO: 72)	#13	ER
<u>Class 5</u>		
S A A C A T I S H Y L M G G (SEQ ID NO: 73)	#48	ER

In the Specification, beginning at page 244, please replace

Table 7 with the following:

Table 7: New Er $\alpha$  Peptide Sequences Immobilized on Plastic

Peptide Name	Peptide Sequence	Isolated in the presence of receptor form	SERM present when peptide was identified
1PT	SRNLCFFWDDEYCSR (SEQ ID NO: 74)	$\alpha$	Tamoxifen & ICI 182,780
2PT	SWDMHQFFWEGVSR (SEQ ID NO: 75)	$\alpha$	Tamoxifen
3PT	SRWHGTLFWQDEQSR (SEQ ID NO: 76)	$\alpha$	Tamoxifen
4PT	SSCKWYEKCSGLWSR (SEQ ID NO: 77)	$\alpha$	Tamoxifen & ICI 182, 780
5PT	SSRMGHVWYDWTFSR (SEQ ID NO: 78)	$\alpha$	Tamoxifen
6PT	SSRLLGDFGGSVVSR (SEQ ID NO: 79)	$\alpha$	Tamoxifen
7PT	SSKYVFGFQVAGGSR (SEQ ID NO: 80)	$\alpha$	Tamoxifen
8PT	SSWAGIKFGKPPHSR (SEQ ID NO: 81)	$\alpha$	Tamoxifen
9PT	SSWSYGKPTFLSSR (SEQ ID NO: 82)	$\alpha$	Tamoxifen
10PT	SRDTGDMWWGRGGSR (SEQ ID NO: 83)	$\alpha$	Tamoxifen
11PT	SSGRYDPFVLNAASR (SEQ ID NO: 84)	$\alpha$	Tamoxifen
12PT	SSSPWWSFNLRDMSR (SEQ ID NO: 85)	$\alpha$	Tamoxifen
13PT	SSWPYLPKREEWASR (SEQ ID NO: 86)	$\alpha$	Tamoxifen
14PT	SSGWIEQKLGRSFSR (SEQ ID NO: 87)	$\alpha$	Tamoxifen
15PT	SSSATSIKVQYQISR (SEQ ID NO: 88)	$\alpha$	Tamoxifen
16PT	SSYLTLGKSMMAISR (SEQ ID NO: 89)	$\alpha$	Tamoxifen
17PT	SSWHSRWDLALGFSR (SEQ ID NO: 90)	$\alpha$	Tamoxifen
18PT	SSGYWGGWDYGAGSR (SEQ ID NO: 91)	$\alpha$	Tamoxifen
19PT	SRDNCGAGLWAGCSR (SEQ ID NO: 92)	$\alpha$	Tamoxifen
1PI	SSSTPGWWEWDWASR (SEQ ID NO: 93)	$\alpha$	ICI 182, 780
2PI	SSYWDGSWRRKETCVCSR (SEQ ID NO: 94)	$\alpha$	ICI 182, 780
3PI	SSRTAEDYCFFADDYWCSR (SEQ ID NO: 95)	$\alpha$	ICI 182, 780
4PI	SSRALALFPVGMESR (SEQ ID NO: 96)	$\alpha$	ICI 182, 780
5PI	SSDCESLTSYPHLKALCSR (SEQ ID NO: 97)	$\alpha$	ICI 182, 780
6PI	SSTATALRDRLAYSR (SEQ ID NO: 98)	$\alpha$	ICI 182, 780
7PI	SSGKTREHYREGTSR (SEQ ID NO: 99)	$\alpha$	ICI 182, 780

In the Specification, at pages 245 - 246, please replace Table 8 with the following:

Table 8: New Er $\alpha$ -ERE Peptide Sequence Information

Peptide Name	Peptide Sequence	Isolated in the presence of receptor form	SERM present when peptide was identified
E1-1	HSNNHHSPWLFRLGG (SEQ ID NO: 100)	$\alpha$	Estradiol
E1-3	HSHPHHSHLLYKLMGG (SEQ ID NO: 101)	$\alpha$	Estradiol
E1-4	HSHPLPPLLSRLLTGG (SEQ ID NO: 102)	$\alpha$	Estradiol
E1-7	SRLTCLLQSNQWDSEQCSR (SEQ ID NO: 103)	$\alpha$	Estradiol
I4-10	SSLTSRDFGWSYASR (SEQ ID NO: 104)	$\alpha$	ICI
T3-1	SRTLQLDWGTLYSR (SEQ ID NO: 105)	$\alpha$	Tamoxifen
T1-10	SRLPPSVFSMCGSEVCLSR (SEQ ID NO: 106)	$\alpha$	Tamoxifen
T2-10	SRFEIWKPEPGCVSSLENWEPGKRVCSR (SEQ ID NO: 107)	$\alpha$	Tamoxifen
T3-11	SRVFGVSGGEVVLINGSSR (SEQ ID NO: 108)	$\alpha$	Tamoxifen
1R	SRLCFGDWCMLGGVDVLSR (SEQ ID NO: 109)	$\alpha$	Raloxifen
2R	SSLNMVVDTPWCGKWVCSR (SEQ ID NO: 110)	$\alpha$	Raloxifen
3B	SSRPDAAFFGAKLSR (SEQ ID NO: 111)	$\alpha$	Buffer
4B	SSRPSPSFWEKQLSR (SEQ ID NO: 112)	$\alpha$	Buffer
5B	SSRPTAEWFRENLSR (SEQ ID NO: 113)	$\alpha$	Buffer
6B	SRWWDTSWWLEELSR (SEQ ID NO: 114)	$\alpha$	Buffer
1B	SSRIADLFWRLPSR (SEQ ID NO: 115)	$\alpha$	Buffer
7B	SRSYHGEWGVWTLR (SEQ ID NO: 116)	$\alpha$	Buffer
10B	SSDWCFGWGGWCASEAVSR (SEQ ID NO: 117)	$\alpha$	Buffer
9B	SRNWDWAALLELLPYPHPSR (SEQ ID NO: 118)	$\alpha$	Buffer
1E	SSLTSRDFGWSYASR (SEQ ID NO: 119)	$\alpha$	Estradiol
2E	SRSPILTHLLSLGSR (SEQ ID NO: 120)	$\alpha$	Estradiol
3E	SSTGILWKLLTAESR (SEQ ID NO: 121)	$\alpha$	Estradiol
9E	SSHGILWRLLSEGSR (SEQ ID NO: 122)	$\alpha$	Estradiol
11E	SRSDSILWRMLSESR (SEQ ID NO: 123)	$\alpha$	Estradiol
4E	SRLVALLKSPWSVSR (SEQ ID NO: 124)	$\alpha$	Estradiol
5E	SRLEELLMLDFWRSR (SEQ ID NO: 125)	$\alpha$	Estradiol
6E	SSKLWQLLSSPIDSR (SEQ ID NO: 126)	$\alpha$	Estradiol
14E	SSKLYCLLDESYCSR (SEQ ID NO: 64)	$\alpha$	Estradiol
7E	SRSLMDMLMSDDYVTVSR (SEQ ID NO: 128)	$\alpha$	Estradiol
8E	SSRLACELMYEDADVCSR (SEQ ID NO: 129)	$\alpha$	Estradiol
15E	HSHSPLLMALLAPPGG (SEQ ID NO: 130)	$\alpha$	Estradiol
10E	SRLEYLRLGTYESR (SEQ ID NO: 131)	$\alpha$	Estradiol
13E	SSCLREILLYGACSR (SEQ ID NO: 132)	$\alpha$	Estradiol
16E	SSRTAEDYCFADDYWCSR (SEQ ID NO: 133)	$\alpha$	Estradiol
17E	SSLRCYLSSSKVDQWACSR (SEQ ID NO: 134)	$\alpha$	Estradiol
18E	SSYKPHSLLEWHLLGGTSR (SEQ ID NO: 135)	$\alpha$	Estradiol

In the Specification at pages 247 - 250, please replace Table 9 with the following:

Table 9: New Er $\beta$ -ERE Peptide Sequence Information

Peptide Name	Peptide Sequence	Isolated in the presence of receptor form	SERM present when peptide was identified
1B- $\beta$	SRLHCLLDSSYCSSR (SEQ ID NO: 136)	$\beta$	Buffer
2B- $\beta$	SRLHCLLDSSYCSSR (SEQ ID NO: 137)	$\beta$	Buffer
3B- $\beta$	SSWPNTFWERQLSR (SEQ ID NO: 138)	$\beta$	Buffer
4B- $\beta$	SYSKEWFEERLNSR (SEQ ID NO: 139)	$\beta$	Buffer
5B- $\beta$	SSSMMREFFERELSR (SEQ ID NO: 140)	$\beta$	Buffer
6B- $\beta$	SSGLPPNFERMLKSR (SEQ ID NO: 141)	$\beta$	Buffer
7B- $\beta$	SSGPWLMHYLGGSR (SEQ ID NO: 142)	$\beta$	Buffer
8B- $\beta$	SSTSWLHHYLMGTSR (SEQ ID NO: 143)	$\beta$	Buffer
9B- $\beta$	SRGGGECLGPWCLSR (SEQ ID NO: 144)	$\beta$	Buffer
12B- $\beta$	SSEACVGRWMLCEQLGVSR (SEQ ID NO: 145)	$\beta$	Buffer
14B- $\beta$	SSQVWPGPWRLVESR (SEQ ID NO: 146)	$\beta$	Buffer
16B- $\beta$	SSSLGPWRLSELESR (SEQ ID NO: 147)	$\beta$	Buffer
17B- $\beta$	SSSGPWRLWGLSIESR (SEQ ID NO: 148)	$\beta$	Buffer
18B- $\beta$	SRECVGGWCLAELSR (SEQ ID NO: 149)	$\beta$	Buffer
19B- $\beta$	SSIPPRSWWLSQLSR (SEQ ID NO: 150)	$\beta$	Buffer
20B- $\beta$	SSWPGAWEFKEQLSR (SEQ ID NO: 151)	$\beta$	Buffer
21B- $\beta$	SSKLYCLLDESYCSR (SEQ ID NO: 152)	$\beta$	Buffer
23B- $\beta$	HSYSSHPLLLSYLWGG (SEQ ID NO: 153)	$\beta$	Buffer
24B- $\beta$	HSWLGPWRLSSIDLGG (SEQ ID NO: 154)	$\beta$	Buffer
25B- $\beta$	HSTDMGWLRPWRLGG (SEQ ID NO: 155)	$\beta$	Buffer
1T- $\beta$	SSVFTIMDGKVALSR (SEQ ID NO: 156)	$\beta$	Tamoxifen
2T- $\beta$	SRPYCLGDVWCLDSR (SEQ ID NO: 157)	$\beta$	Tamoxifen
4T- $\beta$	SREWEDGFGRWLSR (SEQ ID NO: 158)	$\beta$	Tamoxifen
5T- $\beta$	SSWNSREFFLSQLSR (SEQ ID NO: 159)	$\beta$	Tamoxifen
6T- $\beta$	SSTTMFDFFYERLSR (SEQ ID NO: 160)	$\beta$	Tamoxifen
7T- $\beta$	SSARPWWLQFEGSSR (SEQ ID NO: 161)	$\beta$	Tamoxifen
8T- $\beta$	SSQEEWLLPWRLASR (SEQ ID NO: 162)	$\beta$	Tamoxifen
9T- $\beta$	SRLPPSVFSMCGSEVCLSR (SEQ ID NO: 163)	$\beta$	Tamoxifen
10T- $\beta$	SSGPFYVGMLWPADCLSR (SEQ ID NO: 164)	$\beta$	Tamoxifen
12T- $\beta$	SREGWMGPWRLADSR (SEQ ID NO: 165)	$\beta$	Tamoxifen
13T- $\beta$	SRNECIGPWCLTISR (SEQ ID NO: 166)	$\beta$	Tamoxifen
14T- $\beta$	SSPGSREWFKDMLSR (SEQ ID NO: 167)	$\beta$	Tamoxifen
15T- $\beta$	SSVASREWWVRELSR (SEQ ID NO: 168)	$\beta$	Tamoxifen
16T- $\beta$	SRMFQVCGDEVCLRSR (SEQ ID NO: 169)	$\beta$	Tamoxifen
17T- $\beta$	SSDLHRDCLGVWCLSR (SEQ ID NO: 170)	$\beta$	Tamoxifen
18T- $\beta$	SRLNGVFCHDSSDLWVCSR (SEQ ID NO: 171)	$\beta$	Tamoxifen
20T- $\beta$	SRPGCLRGVWCLADTPPSR (SEQ ID NO: 172)	$\beta$	Tamoxifen

21T-β	SSRLVPHSFWLDGLMHGSR (SEQ ID NO: 173)	β	Tamoxifen
22T-β	SSISTYHMGWEFYAMLSSR (SEQ ID NO: 174)	β	Tamoxifen
23T-β	SSDLYSQMREFFQINLSR (SEQ ID NO: 175)	β	Tamoxifen
1E-β	SSRGLLWDLTKDSR (SEQ ID NO: 176)	β	Estradiol
2E-β	SRHGILWDLQGDSR (SEQ ID NO: 177)	β	Estradiol
3E-β	SRLHDLRLRDESPSR (SEQ ID NO: 178)	β	Estradiol
4E-β	SRDWRSGFLYELLSR (SEQ ID NO: 179)	β	Estradiol
5E-β	SSDTRSRLYELLSSSYTSR (SEQ ID NO: 180)	β	Estradiol
6E-β	SRLEELLRVGVLTSR (SEQ ID NO: 181)	β	Estradiol
7E-β	SRLEDLLRGDSKPQSR (SEQ ID NO: 182)	β	Estradiol
8E-β	SSPTGHRLLLESLLLNSNSR (SEQ ID NO: 183)	β	Estradiol
9E-β	SSILERLLGGGSAETV (SEQ ID NO: 184)	β	Estradiol
10E-β	SRSPILWHLLQDGSR (SEQ ID NO: 185)	β	Estradiol
11E-β	SSRTPILFSLLETSR (SEQ ID NO: 186)	β	Estradiol
12E-β	SSIKDFPNLISLLSR (SEQ ID NO: 187)	β	Estradiol
13E-β	SSGSSAGRLMMLLQDGVSR (SEQ ID NO: 188)	β	Estradiol
14E-β	SREGLLMRLLIGDSR (SEQ ID NO: 189)	β	Estradiol
15E-β	SSHCHTRLCSLLTSR (SEQ ID NO: 190)	β	Estradiol
16E-β	SSRLCCLLDAGQCSR (SEQ ID NO: 191)	β	Estradiol
17E-β	SRNLLCCLLDQEACSR (SEQ ID NO: 192)	β	Estradiol
18E-β	SSLKCLLNSNFCSR (SEQ ID NO: 193)	β	Estradiol
19E-β	SSLKCLLQSSPQKQPFCSR (SEQ ID NO: 194)	β	Estradiol
20E-β	SSRTLLEHYLLGGSR (SEQ ID NO: 195)	β	Estradiol
21E-β	SSAGLLEDMLRSRSR (SEQ ID NO: 196)	β	Estradiol
22E-β	SSRCSSLLCEMLIQTKESR (SEQ ID NO: 197)	β	Estradiol
23E-β	SSLQAGSWLMHYLRGGDSR (SEQ ID NO: 198)	β	Estradiol
24E-β	SRPEGSSWLLHYLSR (SEQ ID NO: 199)	β	Estradiol
25E-β	SSRTLLEHYLLGGSR (SEQ ID NO: 200)	β	Estradiol
26E-β	SRWWLDDHELLLYSSR (SEQ ID NO: 201)	β	Estradiol
27E-β	SSRTLYCHLTSSNPEWCSR (SEQ ID NO: 202)	β	Estradiol
28E-β	SSTRLMCWLGSADTSHCSR (SEQ ID NO: 203)	β	Estradiol
29E-β	SSYDWQCPSWYCPAPPSSR (SEQ ID NO: 204)	β	Estradiol
30E-β	SSTTWRCPEWYCGSR (SEQ ID NO: 205)	β	Estradiol
31E-β	SSWDFRVPWWYNNSR (SEQ ID NO: 206)	β	Estradiol
32E-β	SSQWQAPWWYIDASR (SEQ ID NO: 207)	β	Estradiol
33E-β	SSRPSFTIPWWFDDPSRSR (SEQ ID NO: 208)	β	Estradiol
34E-β	SSYEIPKWALQWLSR (SEQ ID NO: 209)	β	Estradiol
35E-β	SSLDLSQFPMTASFLRESR (SEQ ID NO: 210)	β	Estradiol



In the Specification, at page 251, please replace Table 10 with the following:

Table 10: Panel Peptides for Example 2

$\alpha/\beta$  I, SSNHQSSRLIELLSR (AB1) [17 $\beta$ -estradiol] (SEQ ID NO: 211)  
 $\alpha/\beta$  II, SAPRATISHYLMGG (AB2) [no modulator] (SEQ ID NO: 212)  
 $\alpha/\beta$  III, SSWDMHQFFWEGVSR (AB3) [4-OH tamoxifen] (SEQ ID NO: 213)  
 $\alpha/\beta$  IV, SRLPPSVFMSMCGSEVCLSR (AB4) [same] (SEQ ID NO: 214)  
 $\alpha/\beta$  V, SSPGSREWFKDMLSR (AB5) [same] (SEQ ID NO: 215)  
 $\alpha$  I, SSEYCFYWDSAHCSSR (A1) [17 $\beta$ -estradiol] (SEQ ID NO: 216)  
 $\alpha$  II, SSLTSRDFGSWYASR (A2) [17 $\beta$ -estradiol] (SEQ ID NO: 217)  
 $\alpha$  III, SRTWESPLGTWEWSR (A3) [no modulator] (SEQ ID NO: 218)  
 $\beta$  I, SREWEDGFGGRWLSR (B1) [4-OH tamoxifen] (SEQ ID NO: 219)  
 $\beta$  II, SSLDLSQFPMTASFLRESR (B2) [17 $\beta$ -estradiol] (SEQ ID NO: 220)  
 $\beta$  III, SSEACVGRWMLCEQLGVSR (B3) [no modulator] (SEQ ID NO: 221)

Alternative name parenthesized. Modulator used to isolate peptide in brackets.

In the Specification, at page 266, please replace Table 100 with the following:

Table 100

<b>A</b>	S R A G L L S D L L E G K S R	(SEQ ID NO: 222)
	S S R S L L R D L L M V D S R	(SEQ ID NO: 223)
	S S N K L L Y N L L K M E S R	(SEQ ID NO: 224)
	S S K S L L L N L L S T P S R	(SEQ ID NO: 225)
	H S F P R E S L L V R L L Q G G	(SEQ ID NO: 226)
	S R L E M L L R S E T D F S R	(SEQ ID NO: 227)
	S R L E E L L K W G S V T S R	(SEQ ID NO: 228)
	S R L E Q L L K E E F S Y S R	(SEQ ID NO: 229)
	S R L E Q L L R S E P D F S R	(SEQ ID NO: 230)
	S R L E D L L R A P F T T S R	(SEQ ID NO: 231)
	S R L E S L L R F G Q L D S R	(SEQ ID NO: 232)
	S S R L L S L L V G D F N S R	(SEQ ID NO: 233)
	S R L E E L L L G T N R D S R	(SEQ ID NO: 234)
	S R L E E L L L M D F W R S R	(SEQ ID NO: 235)
	S R L K E L L L L P T D L S R	(SEQ ID NO: 236)
	S R L E C L L E G R L N C S R	(SEQ ID NO: 237)
	S S K L Y C L L D E S Y C S R	(SEQ ID NO: 238)
	S R L S C L L M G F E D C S R	(SEQ ID NO: 239)
	S S K L I R L L T S D E E L S R	(SEQ ID NO: 240)
	S S R L M E L L Q E G Q G W S R	(SEQ ID NO: 241)
	S S N H Q S S R L I E L L S R	(SEQ ID NO: 242)
	S S R L W Q L L A S T D T S R	(SEQ ID NO: 243)
	S S K L W Q L L S S P I D S R	(SEQ ID NO: 244)
	S R L V A L L K S P W S V S R	(SEQ ID NO: 245)
	S S N S M L W K L L A A P S R	(SEQ ID NO: 246)
	S S K T L W R L L E G E R S R	(SEQ ID NO: 247)
	S R A G P V L W G L L S E S R	(SEQ ID NO: 248)
	S R S P I L T H L L S L G S R	(SEQ ID NO: 249)
	S S T G I L W K L L T A E S R	(SEQ ID NO: 250)
	S S H G I L W R L L S E G S R	(SEQ ID NO: 251)

<b>B</b>		K L V Q L L T T T A E	(SEQ ID NO: 252)
		I L H R L L Q E G S P	(SEQ ID NO: 253)
	SRC1a	L L R Y L L D K D E K	(SEQ ID NO: 254)
		L L Q Q L L T E	(SEQ ID NO: 255)
CBP		Q L S E L L R G G S G	(SEQ ID NO: 256)
		Q L V L L L H A H K C	(SEQ ID NO: 257)
RIP140		Y L E G L L M H Q A A	(SEQ ID NO: 258)
		L L A S L L Q S E S S	(SEQ ID NO: 259)
		H L K T L L K K S K V	(SEQ ID NO: 260)
		Q L A L L L S S E A H	(SEQ ID NO: 261)

L L L H L L K S Q T I	(SEQ ID NO: 262)
L L Q L L L G H K N E	(SEQ ID NO: 263)
V L Q L L L G N P K G	(SEQ ID NO: 264)
L L S R L L R Q N Q D	(SEQ ID NO: 265)
V L K Q L L L S E N C	(SEQ ID NO: 266)

SRCl $\alpha$  = human steroid receptor coactivator 1 $\alpha$ ,  
CBP = mouse cAMP-responsive element (CREB) - binding 50 protein,  
RIP 140 = human RIP140

In the Specification, at page 267, please replace Table 101 with the following:

Table 101

Class I			
	ER4	SSNHQSRLLIELLSR	(SEQ ID NO: 267)
	D2	GSEPKSRLLLELLSAPVTDV	(SEQ ID NO: 280)
	D30	HPTHSSRLWELLMEATPTM	(SEQ ID NO: 281)
	D11	VESGSSRLMQLLMANDLLT	(SEQ ID NO: 282)
Class II			
	D47	HVYQHPLLLSLLSSEHESG	(SEQ ID NO: 268)
	C33	HVEMHPLLMGLLMESQWGA	(SEQ ID NO: 269)
	D14	QEAHGPLLWNLLSRSDTDW	(SEQ ID NO: 270)
Class III			
	F6	GHEPLTLLERLLMDDKQAV	(SEQ ID NO: 271)
	D22	LPYEGSLLLKLLRAPVEEV	(SEQ ID NO: 272)
	D48	SGWENSILYSLLSDRVSLD	(SEQ ID NO: 273)
	D43	AHGESELLAWLLSGEYSSA	(SEQ ID NO: 274)
	D17	GVFCDSILCQLLAHDNARL	(SEQ ID NO: 275)
	D41	HHNGHSILYGLLAGSDAPS	(SEQ ID NO: 276)
	D26	LGERASLLDMLLRQENPAW	(SEQ ID NO: 277)
	D40	SGWNESTLYRLLQADAFDV	(SEQ ID NO: 278)
	D15	PSGGSSVLEYLLTHDTSIL	(SEQ ID NO: 279)
	F4	PVGEPGLLWRLLSAPVERE	(SEQ ID NO: 284)
Misc.			
	D10	WEEHSQMLLHLLDTGEAVW6	(SEQ ID NO: 283)
ERβsp.	#293	SSIKDFPNLISLLSR	(SEQ ID NO: 187)
GRIP-1	NR1	DSKGQTKLLQLLTTKSDQM	(SEQ ID NO: 16)
	NR2	LKEKHKILHQLLQDSSSPV	(SEQ ID NO: 17)
	NR3	KKKENALLRYLLDKDDTKD	(SEQ ID NO: 18)
SRC-1	NR1	YSQTS HKLVKLLTTTAEQQ	(SEQ ID NO: 19)
	NR2	LTARHKILHRLLQEGSPSD	(SEQ ID NO: 20)
	NR3	ESKDHQLLRYLLDKDEKDL	(SEQ ID NO: 21)

In the Specification, at page 268, please replace Table 202A with the following:

Table 202A: Giα1 GDP/GTPγS-Independent Phage (I-Peptides)

<u>ID</u>	<u>Sequence/Motif Aligned</u>		<u>Liq</u>	<u>Library</u>
99	SRAHLLTWSEFLDSHTK	(SEQ ID NO: 22)	BUF	<u>E</u>
103	SSGELITWYEFLGDLNP	(SEQ ID NO: 23)	BUF	
107	SRGELTTWYEFLSHGRP	(SEQ ID NO: 24)	BUF	<u>E</u>
361	DELTWWEFISD	(SEQ ID NO: 25)	GTP	<u>K</u>
388,391	VTWYDFLMEDTK	(SEQ ID NO: 26)	GTP	<u>CWL</u>
45	GLMTWREFLQE	(SEQ ID NO: 27)	BUF	<u>R</u>
397,401,412	NLMTWYEYLADGERL	(SEQ ID NO: 28)	GTP	<u>Y</u>
15r2,301,394	ADRLWTWQEFly	(SEQ ID NO: 29)	BUF	<u>PHD12</u>
380,381,140	KTYSlyEFLEL	(SEQ ID NO: 30)	GTP	<u>N</u>
16	SSQLLTLHEFLNS	(SEQ ID NO: 31)	BUF	<u>H</u>
360	SSRGEYWWEFLGYSR	(SEQ ID NO: 32)		
101	SSADGIFWWEYAREAGE	(SEQ ID NO: 33)	BUF	
375,123,125,247	LGRGTTDMPPWAWWS	(SEQ ID NO: 34)	GTP	
331,334	NYTERPWVWYH	(SEQ ID NO: 35)	GDP	
37	SSLYSMEPWKWYT	(SEQ ID NO: 36)	BUF	
387	KWWESDWFVNFG	(SEQ ID NO: 37)	GTP	
386	EEGMDWFMRVVE	(SEQ ID NO: 38)	GTP	

In the Specification, at page 270, please replace Table 202B  
 with the following:

Table 202B: Giα1 GTP-Specific Phage  
(T-Peptides)

370,377,378	SVLSSSEMCFGWACY	(SEQ ID NO: 39)	GTP	<u>M</u>
244	SEMCFGWACY	(SEQ ID NO: 40)	GDP	<u>PARO</u>
366,G12	FNEVCLGWQCY	(SEQ ID NO: 41)	GTP	<u>K</u>
G33,G34	SSNARPCQGWHCYLPSQSR	(SEQ ID NO: 42)		
353	WDGGVWMGPAS	(SEQ ID NO: 43)	GTP	<u>K</u>
408	MGDSVLPYGGVWLGP	(SEQ ID NO: 44)	GTP	<u>Y</u>
G22,G25	SRYGGVWLGPENSR	(SEQ ID NO: 45)		
G11,G26-29	SSWDGGVWVGQYGSR	(SEQ ID NO: 46)		
G9,G10	SSNLDGCFTSGGVWSGCSR	(SEQ ID NO: 47)		
382	LGYDINGVWIG	(SEQ ID NO: 48)	GTP	<u>N</u>
384	ICDIIPWEESCSR	(SEQ ID NO: 49)	GTP	<u>P</u>
413	ACGPAICPWDFMPQL	(SEQ ID NO: 50)	GTP	<u>PARO</u>

Note: clone 244, which was identified in a screen for peptide which  
 bound GDP:G-alpha, is suspected to having increased the affinity of  
 the G-alpha for GTP through a conformational change.

In the Specification, at page 272, please replace Table 202C with the following:

Table 202C: Giα1 GDP-Specific Phage  
(D-Peptides)

G4	SRGPQLTWQEFLLTGAASSR	(SEQ ID NO: 51)		
314	NVVTWWEFLGP	(SEQ ID NO: 52)	GDP	
73	SREFVTWKEFLGS	(SEQ ID NO: 53)	BUF	K
343	SQLTWREFLFG	(SEQ ID NO: 54)	GDP	R
217	SSHLMTWHEFISD	(SEQ ID NO: 55)	GDP	H
93	SRDGFETWAEFLGASGS	(SEQ ID NO: 56)	BUF	
62	SRLTWSEYLSEIDP	(SEQ ID NO: 57)	BUF	CWL
193	SRTVTWVDFLKET	(SEQ ID NO: 58)	GDP	D
324	MSWYEFMTTEESM	(SEQ ID NO: 285)	GDP	CWI
400	AKHDLSWYEFLLQLPI	(SEQ ID NO: 286)	GTP	V
281	SRLSWWEFLGASDCGTC	(SEQ ID NO: 287)	GDP	X14C<W>
359,161	DLLSLKEFLAT	(SEQ ID NO: 288)	GTP	K
176	SSPNLLTLEEFLLS	(SEQ ID NO: 289)	GDP	L
380,381,140	KTYSLYEFLEL	(SEQ ID NO: 290)	GTP	N
409,24r2	MSNRYTIYEFLLNLHS	(SEQ ID NO: 291)	GTP	Y
320	LHWWEVLAEK	(SEQ ID NO: 292)	GDP	CWL
230	SSPQPLLHWWEEMTEPP	(SEQ ID NO: 293)	GDP	KNK
213	SRAGESVHWWEVL	(SEQ ID NO: 294)	GDP	H
266	RAGPSEHWWEYIATL	(SEQ ID NO: 295)	GDP	N
237	EMISWHQYLLSIENN	(SEQ ID NO: 296)	GDP	PARO
126,128,133,242,248	SSLRWDEFLMELGGGVA	(SEQ ID NO: 297)	BUF	M
379	VPWWVWLAEGD	(SEQ ID NO: 298)	GTP	N
196	SREIYWWDWLTD	(SEQ ID NO: 299)	GDP	D
117	FGSNMLDLPTFLDWL	(SEQ ID NO: 300)	BUF	PARO
92	SRITFWELMLEGG	(SEQ ID NO: 301)	BUF	L
179	SRTPYEWLGYWGA	(SEQ ID NO: 302)	GDP	L
289	YDMCTWLEFLDGGEC	(SEQ ID NO: 303)	GDP	
	X14CW			
265	SPLCTWAEYLMPEPSC	(SEQ ID NO: 304)	GDP	N
273	TQWCTWAEFLSSTDC	(SEQ ID NO: 305)	GDP	M
272,282,6R2	SSDGCTWQEFLLAGHGPC	(SEQ ID NO: 306)	GDP	N
337,339	PFNNPPWMWWS	(SEQ ID NO: 307)	GDP	P
268	SSPTVHENLPPWLWWSP	(SEQ ID NO: 308)	GDP	N
330	LIHVPPWAWYD	(SEQ ID NO: 309)	GDP	P
329	GFDVPPWYWDF	(SEQ ID NO: 310)	GDP	P
280	YSQVFGDAPVWAWYSSR	(SEQ ID NO: 311)	GDP	
	X14CW			
319	WTPSDWQWWRSK	(SEQ ID NO: 312)	GDP	CWL
115	SSHWSDSIFPGFWYSG	(SEQ ID NO: 313)	BUF	PARO
197	SRGGVDLDIGNSA	(SEQ ID NO: 314)	GDP	D
347	EGEDVRTRIAN	(SEQ ID NO: 315)	GDP	R